RBC Capital Keeps Vale SA (VALE) As Hold; Has Target Price Of $11.0; 17 Analysts Covering Spark Therapeutics (ONCE)

November 15, 2017 - By Winifred Garcia

Among 20 analysts covering Spark Therapeutics (NASDAQ:ONCE), 17 have Buy rating, 1 Sell and 2 Hold. Therefore 85% are positive. Spark Therapeutics had 43 analyst reports since August 21, 2015 according to SRatingsIntel. The firm has “Buy” rating by Cantor Fitzgerald given on Thursday, June 23. As per Thursday, July 6, the company rating was maintained by BMO Capital Markets. Cantor Fitzgerald initiated Spark Therapeutics Inc (NASDAQ:ONCE) rating on Friday, June 3. Cantor Fitzgerald has “Buy” rating and $100 target. Cowen & Co maintained the shares of ONCE in report on Wednesday, August 2 with “Buy” rating. The firm has “Outperform” rating given on Friday, October 13 by BMO Capital Markets. The stock of Spark Therapeutics Inc (NASDAQ:ONCE) earned “Hold” rating by Wunderlich on Thursday, December 24. Zacks downgraded Spark Therapeutics Inc (NASDAQ:ONCE) on Wednesday, September 2 to “Sell” rating. The firm has “Buy” rating by Jefferies given on Tuesday, July 11. The firm has “Buy” rating given on Tuesday, October 10 by Stifel Nicolaus. On Friday, August 21 the stock rating was downgraded by Zacks to “Hold”. See Spark Therapeutics Inc (NASDAQ:ONCE) latest ratings:

07/11/2017 Broker: J.P. Morgan Rating: Buy New Target: $92.0
07/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $105.0 Maintain
25/10/2017 Broker: RBC Capital Markets Rating: Buy New Target: $100.0 Maintain
13/10/2017 Broker: SunTrust Rating: Buy New Target: $101.0 Maintain
13/10/2017 Broker: Barclays Capital Rating: Overweight Old Target: $104 New Target: $107 Maintain
13/10/2017 Broker: BMO Capital Markets Rating: Outperform Old Target: $89 New Target: $101 Maintain
12/10/2017 Broker: Raymond James Rating: Outperform New Target: $96 Initiates Coverage On
10/10/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $92.0 Maintain
10/10/2017 Broker: BMO Capital Markets Rating: Buy New Target: $89.0 Maintain
10/10/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $94.0 Maintain




Among 24 analysts covering Vale S.A. (NYSE:VALE), 10 have Buy rating, 1 Sell and 13 Hold. Therefore 42% are positive. Vale S.A. has $1200 highest and $2.50 lowest target. $7.92’s average target is -17.41% below currents $9.59 stock price. Vale S.A. had 65 analyst reports since August 3, 2015 according to SRatingsIntel. The stock has “Hold” rating by BMO Capital Markets on Monday, July 31. The rating was downgraded by Vetr on Friday, August 28 to “Strong-Buy”. RBC Capital Markets maintained it with “Sector Perform” rating and $5.50 target in Friday, May 6 report. The company was maintained on Friday, November 20 by Cowen & Co. Jefferies maintained the shares of VALE in report on Friday, July 28 with “Hold” rating. The firm earned “Equal-Weight” rating on Wednesday, September 21 by Barclays Capital. The stock has “Hold” rating by RBC Capital Markets on Wednesday, September 6. The company was maintained on Thursday, July 27 by Credit Suisse. The firm has “Buy” rating given on Monday, January 23 by Citigroup. RBC Capital Markets maintained it with “Sector Perform” rating and $7 target in Monday, August 3 report.

Spark Therapeutics, Inc. is a gene therapy company. The company has market cap of $2.53 billion. The Firm focuses on treating orphan diseases. It currently has negative earnings. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases.

Investors sentiment increased to 1.81 in Q2 2017. Its up 0.61, from 1.2 in 2017Q1. It increased, as 7 investors sold Spark Therapeutics Inc shares while 29 reduced holdings. 19 funds opened positions while 46 raised stakes. 27.22 million shares or 1.96% more from 26.70 million shares in 2017Q1 were reported. Prelude Cap Mgmt Limited Co invested in 5,387 shares. 117,121 are owned by Bank & Trust Of Mellon. Jefferies Gru Limited Liability Corporation holds 8,033 shares or 0% of its portfolio. The New York-based Bnp Paribas Arbitrage Sa has invested 0% in Spark Therapeutics Inc (NASDAQ:ONCE). Amg Natl Tru Fincl Bank reported 5,000 shares. Highland Capital L P has 0.1% invested in Spark Therapeutics Inc (NASDAQ:ONCE) for 40,300 shares. Aqr Cap Ltd holds 0% or 9,894 shares. Deutsche Bancorp Ag reported 0.01% stake. Glenmede Tru Na reported 8,302 shares. Price T Rowe Incorporated Md, a Maryland-based fund reported 3.17M shares. Moreover, Ghost Tree Lc has 0.43% invested in Spark Therapeutics Inc (NASDAQ:ONCE) for 35,000 shares. Philadelphia stated it has 0.03% in Spark Therapeutics Inc (NASDAQ:ONCE). Blackrock, New York-based fund reported 2.05 million shares. Moreover, Millennium Mgmt Lc has 0.06% invested in Spark Therapeutics Inc (NASDAQ:ONCE) for 535,631 shares. Endurant Cap Mgmt Lp stated it has 4,700 shares or 0.08% of all its holdings.

The stock decreased 6.06% or $4.4 during the last trading session, reaching $68.25. About shares traded. Spark Therapeutics Inc (NASDAQ:ONCE) has risen 13.53% since November 15, 2016 and is uptrending. It has underperformed by 3.17% the S&P500.

Analysts await Vale SA (ADR) (NYSE:VALE) to report earnings on February, 22. They expect $0.20 EPS, down 62.26% or $0.33 from last year’s $0.53 per share. VALE’s profit will be $1.08 billion for 11.99 P/E if the $0.20 EPS becomes a reality. After $0.40 actual EPS reported by Vale SA (ADR) for the previous quarter, Wall Street now forecasts -50.00% negative EPS growth.

Vale S.A. is a global producer of iron ore and iron ore pellets, key raw materials for steelmaking, and producer of nickel. The company has market cap of $51.67 billion. The Firm also produces copper, metallurgical and thermal coal, potash, phosphates and other fertilizer nutrients, manganese ore, ferroalloys, platinum group metals, gold, silver and cobalt. It has a 7.59 P/E ratio.

About 19,100 shares traded. Vale SA (ADR) (NYSE:VALE) has risen 111.11% since November 15, 2016 and is uptrending. It has outperformed by 94.41% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.